2025-04-03 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**0. Key Figures:**

* **Cumulative Return (MRK):** 34.10%
* **Cumulative Return (VOO):** 89.44%
* **Return Difference (MRK vs VOO):** -55.3%
* **Relative Return Difference:** 19.1% (This indicates MRK's underperformance relative to VOO is in the 19.1st percentile of historical relative performance, considering the maximum and minimum difference observed over the analysis period.  It is not a percentage point difference)
* **Current Price:** $87.12
* **Last Market Change:** -$0.72 (-0.83%)


**1. Company Overview & Performance Comparison:**

Merck & Co Inc is a leading pharmaceutical company.  Over the analyzed period, MRK significantly underperformed the S&P 500 (VOO), with a cumulative return considerably lower than VOO's. The relative underperformance is in the lower part of the historical distribution, but not at the extreme low end.

**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|-------|-------|
| 2015-2017  | 2.0% | 14.0% | -16.0% | 108.2 |
| 2016-2018  | 43.0% | 14.0% | 36.0% | 151.4 |
| 2017-2019  | 44.0% | 14.0% | 25.0% | 185.2 |
| 2018-2020  | 25.0% | 10.4% | -9.0% | 171.8 |
| 2019-2021  | -2.0% | 14.2% | -75.0% | 174.8 |
| 2020-2022  | 31.0% | 45.4% | 20.0% | 261.2 |
| 2021-2023  | 45.0% | 45.4% | 27.0% | 263.9 |
| 2022-2024  | 14.0% | 45.4% | -9.0% | 247.4 |
| 2023-2025  | -35.0% | 50.6% | -76.0% | 218.5 |


The table shows significant volatility in CAGR and considerable negative alphas in some periods, suggesting periods of underperformance relative to the market benchmark.  The beta values fluctuate, suggesting varying sensitivities to market movements. The negative alpha values suggest underperformance compared to the market in those periods, whereas positive alpha suggests outperformance.


**2. Recent Price Movement:**

* **Closing Price:** $87.12
* **5-Day Moving Average:** $88.36
* **20-Day Moving Average:** $92.07
* **60-Day Moving Average:** $92.52

The price is below all three moving averages, indicating a potential downward trend.  The recent price drop (-$0.72) further supports this observation.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4354 (Medium Risk)
* **RSI:** 33.45 (Suggests oversold conditions)
* **PPO:** -0.6978 (Negative PPO suggests bearish momentum)
* **Recent Relative Strength Change (20-day):** +3.0 (Short-term upward momentum)
* **Expected Return (Long-Term):** 14.1% (This represents a potential outperformance of the S&P 500 over the long term (2+ years), assuming continued investment)

The conflicting signals from the RSI (oversold), PPO (bearish), and recent relative strength change suggest uncertainty. The recent price drop reflects negative market sentiment.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      | *(Duplicate entry - likely an error in the data)*

Revenue is relatively stable, but EPS shows significant variability, with a notable drop in the most recent quarter (1.25 vs. 2.15 the prior quarter). This volatility needs further investigation to determine underlying causes.  The duplicate entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |

Revenue shows some fluctuation, while profit margins are generally high and relatively stable.  There's a slight downward trend in recent quarters.


**Capital and Profitability:**

| Quarter | Equity     | ROE         |
|---------|------------|-------------|
| 2024-12-31 | $46.31B   | 8.08%       |
| 2024-09-30 | $44.50B   | 7.09%       |
| 2024-06-30 | $43.58B   | 12.52%      |
| 2024-03-31 | $40.36B   | 11.80%      |
| 2023-12-31 | $37.58B   | -3.26%      |

Equity is increasing, but ROE shows considerable variability, with a negative value in the last quarter of 2023. This requires further investigation to understand the underlying reasons for the fluctuations.

**6. Overall Conclusion:**

MRK's performance has lagged the S&P 500 significantly over the analyzed period. While long-term expected returns are positive, recent price action and earnings data reveal concerns.  The relatively high profit margins are positive, but the volatility in EPS, ROE, and the recent price drop below moving averages raise concerns.  Further investigation into the causes of the EPS and ROE fluctuations, as well as a deeper dive into the companyâ€™s fundamentals and future prospects, are necessary to form a complete investment opinion. The data suggests a medium-risk profile at present, and while a long-term investment may offer potential upside, careful monitoring of market conditions and company performance is strongly recommended.  The conflicting signals from technical indicators also add to the uncertainty. The duplicate entry in the earnings data highlights the need for data verification before making any investment decisions.
